Showing results (11-20 of 50) with videos related to
Sort By:
Pageof 5
Lipids|November 1, 1987
Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patientsD B Herrmann, H A Neumann, W E Berdel, et al.Journal of Immunopharmacology|January 1, 1985
Ciamexone--a new highly selective immunosuppressive compoundU Bicker, W PahlkeJournal of Immunopharmacology|January 1, 1981
Effect of the immune modulators BM 12.531 (azimexone) and BM 41.332 on the subsets of T-lymphocytes in miceL Olsson, U BickerExperimentelle Pathologie|January 1, 1975
Carcinostatic action of 2-cyanaziridines against a sarcoma in ratsU Bicker, P FuhseKlinische Wochenschrift|December 15, 1986
Ciamexone, a highly selective immunomodulator--a tool for autoimmune diseases?U Bicker, K H UsadelJournal of Immunopharmacology|January 1, 1983
Optimizing the lymphocyte transformation test in whole blood. II. Kinetics of thymidine incorporationW Schaumann, U Bicker, V HaasJournal of Immunopharmacology|January 1, 1983
Optimizing the lymphocyte transformation test in whole blood. I. Optimum conditions for thymidine incorporationU Bicker, W Schaumann, V HaasThe Journal of Infectious Diseases|April 1, 1979
Investigations in mice on the potentiation of resistance to infections by a new immunostimulant compoundU Bicker, A E Ziegler, G HeboldJournal of Immunopharmacology|January 1, 1984
Investigations on the age-dependence of T-lymphocyte subpopulations and lymphocyte reactivityJ J Reiter, G Ehrlich, U BickerExperimentelle Pathologie|January 1, 1977
Experimental investigations on increased resistance to infections with Candida albicans and Staphylococcus aureus Smith by 4-imino-1,4-diazobicyclo-(3.1.0)-hexane-2-on BM 06.002 (prop. INN imexon) in miceA E Ziegler, U Bicker, G HeboldPageof 5